Technical analysis of Actuate Therapeutics Inc (ACTU): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer.
Price Performance
| 1 month | -5.01% |
| 3 months | -51.82% |
| Year-to-date | -83.70% |
| 1 year | -85.59% |
52-Week Range
| 52-week High | $8.49 |
| 52-week Low | $0.90 |
| Avg Volume (90d) | 308K |
Technical Indicators
| SMA 50 | $1.26 |
| SMA 200 | $3.13 |
| Beta | 0.86 |
| 30-day Volatility (annualised) | 133.2% |
| Price vs SMA 50 | -20.9% |
| Price vs SMA 200 | -68.1% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $6.66 | |
| 2025-11 | $7.63 | +14.6% |
| 2025-12 | $6.12 | -19.8% |
| 2026-01 | $4.71 | -23.0% |
| 2026-02 | $3.74 | -20.6% |
| 2026-03 | $2.74 | -26.7% |
| 2026-04 | $2.94 | +7.3% |
| 2026-05 | $2.02 | -31.3% |
| 2026-06 | $1.53 | -24.3% |
| 2026-07 | $1.11 | -27.5% |
| 2026-08 | $1.52 | +36.9% |
| 2026-09 | $1.00 | -34.4% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-15 | | |
| 2026-09-15 | $-0.02 | |
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | | |
Price
| Price | $1.00 |
| Market Cap | $24M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 27.40 |
| EV / EBITDA | -5.22 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.41 |
| Current Ratio | 1.25 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -7.40 |